Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Rhabdomyosarcoma

Rhabdomyosarcoma

Part of Epithelioid Sarcoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Rhabdomyosarcoma

18 trials tracked for Rhabdomyosarcoma: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 180 citations.

18Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 15 Other / NA 2
  1. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed · 180 cited
  2. Phase 2 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed
  3. Phase 2 SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Completed
  4. Phase 2 Trial of Afatinib in Pediatric Tumours Completed
  5. Phase 2 Trial of Dasatinib in Advanced Sarcomas Completed
  6. Phase 2 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed
Show 12 more trials
  1. Phase 2 A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Completed
  2. Phase 2 Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors Completed
  3. Phase 2 Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI Completed
  4. Phase 2 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed
  5. Phase 2 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Completed
  6. Phase 2 Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Completed
  7. Phase 2 A Study of Pemetrexed in Children With Recurrent Cancer Completed
  8. Phase 2 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed
  9. Phase 2 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Completed
  10. Phase 2 A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping Completed
  11. N/A Molecular-Guided Therapy for Childhood Cancer Completed
  12. N/A Proton Radiation Therapy (RT) for the Treatment of Pediatric Rhabdomyosarcoma Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Rhabdomyosarcoma: what the trials found

Clinical evidence confirms that nab-paclitaxel is an established intervention in the treatment of rhabdomyosarcoma [2, 10].

Regarding cyclophosphamide, research indicates that there was no statistically significant difference (p=0.99) in the incidence of toxicity related to VI treatment across different UGT1A1 genotypes 1.

Recent results — preliminary, needs further review

  • Tc99m tilmanocept 3
  • Surufatinib in combination with Gemcitabine 4
  • Regorafenib 5
  • Vemurafenib (75% of patients experienced Grade 3 or higher adverse events) 6
  • Eribulin mesilate 7

For the clinician treating this condition

  • Nab-paclitaxel is established as a treatment option for rhabdomyosarcoma.
  • Cyclophosphamide administration does not appear to show significant toxicity variance based on UGT1A1 genotype.
  • Experimental modalities including proton beam radiation, various targeted therapies (e.g., Vemurafenib, afatinib), and immunotherapies are currently under investigation.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds MyoD1 immunopositivity common in retroperitoneal spindle cell/sclerosing rhabdomyosarcoma
Oncology Meta-analysis
Meta-analysis finds MyoD1 immunopositivity common in retroperitoneal spindle cell/sclerosing rhabdomyosarcoma What makes a rare, aggressive abdominal cancer so hard to treat?
A meta-analysis and institutional case series examined adult patients with retroperitoneal spindle cell/sclerosing rhabdomyosarcoma (Sc/SRMS…
A rare abdominal cancer often grows huge and invades nearby organs like kidneys, with a third of cases carrying a specific gene mutation.
Frontiers Apr 2, 2026